MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:
Bryan Garnier 4th Healthcare Conference
Date: November 14, 2016
Venue: Paris, France
Presenter: Dr. Claudia Gutjahr-Löser & Anke Linnartz
Head of Corporate Communications & IR
HSBC Healthcare Day 2016
Date: November 17, 2016
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
Eigenkapitalforum 2016
Date: November 21, 2016
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
13th Kempen & Co Life Sciences Conference
Date: November 23, 2016
Venue: London, UK
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
dbAccess Pharmaceutical & Healthcare Corporate Day
Date: December 1, 2016
Venue: London, UK
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
American Society of Hematology (ASH) Annual Meeting 2016
Date: December 5, 2016
MorphoSys will hold an Investor & Analyst Event at the 2016 ASH Annual Meeting. Clinical data published at the medical conference will be presented.
A PDF version of all presentations will be provided at www.morphosys.com.
The link to webcasts will be filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
Date: November 14, 2016
Venue: Paris, France
Presenter: Dr. Claudia Gutjahr-Löser & Anke Linnartz
Head of Corporate Communications & IR
HSBC Healthcare Day 2016
Date: November 17, 2016
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
Eigenkapitalforum 2016
Date: November 21, 2016
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
13th Kempen & Co Life Sciences Conference
Date: November 23, 2016
Venue: London, UK
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
dbAccess Pharmaceutical & Healthcare Corporate Day
Date: December 1, 2016
Venue: London, UK
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
American Society of Hematology (ASH) Annual Meeting 2016
Date: December 5, 2016
MorphoSys will hold an Investor & Analyst Event at the 2016 ASH Annual Meeting. Clinical data published at the medical conference will be presented.
A PDF version of all presentations will be provided at www.morphosys.com.
The link to webcasts will be filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
